t
| Date | 1 Oct 2021 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 6313N |
RNS | 1 OCTOBER 2021
ImmuPharma PLC
("ImmuPharma", the "Company" or the "Group")
EURONEXT DELISTING
Date: 18 October 2021
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, provides an update on its delisting from the Euronext Growth Brussels market, where it has a dual listing with AIM. This proposed de-listing from Euronext Growth Brussels was recently confirmed in the Company's 'Corporate Update' announcement on 29 September 2021.
The Company has received confirmation that the Euronext Listing Board has approved its voluntary delisting request from Euronext Growth Brussels.
The timeframe of the de-listing has been agreed with Euronext. It is envisaged that the shares of ImmuPharma (ISIN: GB0033711010) will be removed from trading on Euronext Growth Brussels, as from the 18 October 2021.
Below is a summary of the delisting schedule as disclosed:
|
DATE |
EVENT |
|
15 October 2021 |
Last day of trading of ImmuPharma's shares on Euronext Growth Brussels |
|
18 October 2021 |
ImmuPharma's shares de-listed from Euronext Growth Brussels |
End
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.